Use of Oxprenolol in Cardiac Arrhythmias Associated with Acute Myocardial Ischaemia

Overview

Journal Br Med J

Specialty General Medicine

Date 1971 Jan 30

PMID 5100496

Citations 6

Authors

G Sandler

A C Pistevos

Affiliations

Soon will be listed here.

Abstract

Oxprenolol, a new beta-receptor blocking drug with intrinsic sympathomimetic activity, was used to treat 63 episodes of cardiac arrhythmia occurring in 43 patients with acute myocardial infarction or myocardial ischaemia. The drug was most effective in abolishing ventricular ectopic beats and supraventricular tachycardia. The best method of administration was by continuous intravenous infusion and the most satisfactory bolus does was 6 mg. The main side effect was hypotension, which occurred in 59% of episodes of arrhythmia that had responded previously to intravenous administration. Oxprenolol was often effective in lignocaine-resistant arrhythmia. The two main advantages of oxprenolol over propranolol are the reduced likelihood of adversely affecting myocardial function and the diminished tendency to produce bronchospasm.

Citing Articles

Comparative haemodynamic dose-response effects of intravenous propranolol and pindolol in patients with coronary heart disease.

Silke B, Nelson G, Ahuja R, Okoli R, Taylor S Eur J Clin Pharmacol. 1983; 25(2):157-65.

PMID: 6628498 DOI: 10.1007/BF00543785.

Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction.

Rossi P, Yusuf S, Ramsdale D, Furze L, Sleight P Br Med J (Clin Res Ed). 1983; 286(6364):506-10.

PMID: 6186329 PMC: 1546543. DOI: 10.1136/bmj.286.6364.506.

Intravenous practolol.

Jachuck S, Husaini M Br Med J. 1971; 4(5782):298.

PMID: 4399381 PMC: 1799583. DOI: 10.1136/bmj.4.5782.298-a.

Effects of tiprenolol, practolol and propranolol on experimental ventricular tachyarrhythmias.

Allen J, Shanks R Br J Pharmacol. 1974; 51(2):179-85.

PMID: 4155971 PMC: 1776753. DOI: 10.1111/j.1476-5381.1974.tb09645.x.

Beta-adrenergic receptor blocking drugs in cardiac arrhythmias.

Singh B, Jewitt D Drugs. 1974; 7(6):426-61.

PMID: 4153572 DOI: 10.2165/00003495-197407060-00004.

References

Williams E . Mode of action of beta receptor antagonists on cardiac muscle. Am J Cardiol. 1966; 18(3):399-405. DOI: 10.1016/0002-9149(66)90062-2. View

BATH J . Treatment of cardiac arrhythmias in unanesthetized patients. Role of adrenergic beta receptor blockade. Am J Cardiol. 1966; 18(3):415-25. DOI: 10.1016/0002-9149(66)90064-6. View

SZEKELY P, Jackson F, WYNNE N, Vohra J, BATSON G, Dow W . Clinical observations on the use of propranolol in disorders of cardiac rhythm. Am J Cardiol. 1966; 18(3):426-30. DOI: 10.1016/0002-9149(66)90065-8. View

Stock J . Beta adrenergic blocking drugs in the clinical management of cardiac arrhythmias. Am J Cardiol. 1966; 18(3):444-9. DOI: 10.1016/0002-9149(66)90068-3. View

Stephen S . Unwanted effects of propranolol. Am J Cardiol. 1966; 18(3):463-72. DOI: 10.1016/0002-9149(66)90071-3. View

Epstein S, Braunwald E . Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med. 1966; 275(20):1106-12 contd. DOI: 10.1056/NEJM196611172752006. View

IRONS Jr G, Ginn W, ORGAIN E . Use of a beta adrenergic receptor blocking agent (propranolol) in the treatment of cardiac arrhythmias. Am J Med. 1967; 43(2):161-70. DOI: 10.1016/0002-9343(67)90160-x. View

Grandjean T, RIVIER J . Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba. Br Heart J. 1968; 30(1):50-9. PMC: 459207. DOI: 10.1136/hrt.30.1.50. View

WAAL H . Hypotensive, antiarrhythmic and chronotropic action of Trasicor (Ciba 39089--Ba). N Z Med J. 1968; 67(429):291-5. View

10.

Brunner H, HEDWALL P, Meier M . [Pharmacological studies with 1-isopropylamino-3-(o-allyloxyphenoxy)-2-propanol-hydrochloride, an adrenergic beta-receptor blocking agent]. Arzneimittelforschung. 1968; 18(2):164-70. View

11.

THEILEN E, Wilson W . Beta-adrenergic receptor blocking drugs in the treatment of cardiac arrhythmias. Med Clin North Am. 1968; 52(5):1017-29. View

12.

Wilson D, Watson O, PEEL J, LANGLEY R, Turner A . Some haemodynamic effects of trasicor (Ciba 39,089-Ba). N Z Med J. 1968; 68(436):145-9. View

13.

BEUMER H . [Inhalation of beta adrenergic receptor blockers in asthmatic patients]. Med Klin. 1968; 63(48):1939-40. View

14.

Jewitt D, Reid D, Thomas M, Mercer C, VALORI C, Shillingford J . Free noradrenaline and adrenaline excretion in relation to the development of cardiac arrhythmias and heart-failure in patients with acute myocardial infarction. Lancet. 1969; 1(7596):635-41. DOI: 10.1016/s0140-6736(69)92009-1. View

15.

Bender F . [On the problem of dosage in the treatment of sinus tachycardia using beta-receptor-blocking agents]. Med Welt. 1968; 45:2481-3. View

16.

Dorph S, Binder C . Evaluation of the hypotensive effect of beta-adrenergic blockade in hypertension. Acta Med Scand. 1969; 185(5):443-8. DOI: 10.1111/j.0954-6820.1969.tb07362.x. View

17.

NAYLER W, Chipperfield D, Lowe T . The negative inotropic effect of adrenergic betareceptor blocking drugs on human heart muscle. Cardiovasc Res. 1969; 3(1):30-6. DOI: 10.1093/cvr/3.1.30. View

18.

Sandler G, Clayton G . Clinical evaluation of practolol, a new cardioselective beta-blocking agent in angina pectoris. Br Med J. 1970; 2(5706):399-402. PMC: 1700305. DOI: 10.1136/bmj.2.5706.399. View

19.

Stock J, Dale N . BETA-ADRENERGIC RECEPTOR BLOCKADE IN CARDIAC ARRHYTHMIAS. Br Med J. 1963; 2(5367):1230-3. PMC: 1873329. DOI: 10.1136/bmj.2.5367.1230. View

20.

McNeill R . EFFECT OF A BETA-ADRENERGIC-BLOCKING AGENT, PROPRANOLOL, ON ASTHMATICS. Lancet. 1964; 2(7369):1101-2. DOI: 10.1016/s0140-6736(64)92617-0. View